national institute for Health Protection
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
Invivyd working with FDA towards potential Biologics License Application for COVID-19
The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment
FDA approves Pfizer and BioNTech’s jab for COVID-19
Globally, five billion doses of the companies’ vaccine have been distributed
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive
Kostaive is designed to instruct the body to make more mRNA to boost immune response
WHO urges US to ‘reconsider’ withdrawal from global health organisation
President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises
Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines
The combined vaccine approach could simplify immunisation practices and lead to higher uptake
Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults
Lagevrio is already available in the US under emergency use authorisation to treat certain cases of COVID-19
Seven strategic steps to enhance patient recruitment & retention in your influenza studies
The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...
Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study
The serious adverse event reported was found to be unrelated to the vaccine
Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation
The updated vaccine was shown to generate an improved response against currently circulating variants